Highlighting the importance of this IGF2BP2-IL13-CTGF axis in pathology, blockade of the IL-13 receptor in a mouse nonalcoholic steatohepatitis (NASH) model reduced fibrosis [113]. Here, IGF2BP2 is linked to metabolic dysfunction-associated steatohepatitis.